Platform Technology Partners Purchases 141 Shares of Illumina, Inc. (NASDAQ:ILMN)

Platform Technology Partners increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 4.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,512 shares of the life sciences company’s stock after buying an additional 141 shares during the period. Platform Technology Partners’ holdings in Illumina were worth $458,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Versant Capital Management Inc lifted its position in shares of Illumina by 292.9% in the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after buying an additional 246 shares during the last quarter. Industrial Alliance Investment Management Inc. bought a new stake in Illumina in the 2nd quarter valued at $34,000. Massmutual Trust Co. FSB ADV lifted its holdings in Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after purchasing an additional 168 shares during the last quarter. Itau Unibanco Holding S.A. bought a new position in Illumina during the second quarter worth $61,000. Finally, Mizuho Securities Co. Ltd. acquired a new position in shares of Illumina in the second quarter valued at $63,000. 89.42% of the stock is owned by institutional investors.

Illumina Stock Up 0.3 %

Shares of ILMN opened at $151.50 on Tuesday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 0.86 and a current ratio of 2.43. Illumina, Inc. has a 52 week low of $92.26 and a 52 week high of $156.66. The stock has a market capitalization of $24.03 billion, a price-to-earnings ratio of -15.21 and a beta of 1.13. The stock has a fifty day moving average of $138.50 and a 200-day moving average of $123.77.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same period last year, the company earned $0.33 earnings per share. The business’s quarterly revenue was down 3.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ILMN. HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price for the company in a research note on Thursday, October 17th. UBS Group boosted their price objective on Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Barclays increased their target price on Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Scotiabank decreased their price objective on Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a report on Thursday, August 15th. Finally, JPMorgan Chase & Co. increased their price objective on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Illumina currently has an average rating of “Moderate Buy” and a consensus target price of $164.00.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.